Biodexa Pharmaceuticals (BDRX) announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17/391.495 titled “Oral Rapamycin Nanoparticle Preparations and Use” which was exclusively licensed to Biodexa by Rapamycin Holdings, Inc. d/b/a Emtora Biosciences, along with other patents, in a transaction which closed in April 2024. The patent is due to issue on March 4, 2025 and, in the absence of any patent term extensions, is expected to expire in March, 2034.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biotech Alert: Searches spiking for these stocks today
- Biodexa Pharmaceuticals to Present at Emerging Growth Conference
- Biodexa Pharmaceuticals receives Fast Track designation for eRapa
- Biodexa Pharmaceuticals Receives FDA Fast Track for eRapa in FAP Treatment
- Biodexa Pharmaceuticals Enhances Leadership with New Chief Medical Officer